Clinical Trials Browser

Neoplasms × Bevacizumab × 90 days × Clear all

NCT05359861 2026-03-18

Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT05468359 2026-03-16

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Phase 1/2 Recruiting

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT05862285 2026-03-13

UmbrellaMAX

Phase 3 Recruiting

Neoplasms

NCT07079631 2026-03-06

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

Phase 1/2 Recruiting

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT07024784 2026-03-04

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasms

NCT06252649 2026-02-27

CodeBreaK 301

Phase 3 Recruiting

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT05445778 2026-02-23

GLORIOSA

Phase 3 Recruiting

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT05647122 2026-02-20

EGRET

Phase 1 Recruiting

GastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasms, Colorectal Neoplasms

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT05797246 2026-01-26

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

Phase 2 Active not recruiting

DNA Virus Infections, Infections, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Pathologic Processes, Recurrence, Respiratory Tract Diseases, Respiratory Tract Infections, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Disease Attributes, Papillomavirus Infections

NCT01445509 2026-01-15

Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT03148418 2026-01-13

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Phase 3 Active not recruiting

Neoplasms

NCT05112965 2026-01-07

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Phase 3 Active not recruiting

Neoplasms

NCT07277270 2026-01-07

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

Phase 1 Recruiting

Gastrointestinal

Neoplasms, Colorectal Neoplasms